ADVA
13.7.2021 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced the Cyprus Telecommunications Authority (Cyta) is leveraging its timing technology in a national synchronization network, addressing legacy timing applications and ensuring a smooth migration to precise packet timing for 5G critical services in the future. The solution enables Cyta to meet the stringent timing requirements of next-generation services while supporting all existing mobile technologies. ADVA’s Oscilloquartz PTP grandmaster clock and GNSS receiver technology not only enhances synchronization precision but also provides new levels of resilience and reliability. The project was facilitated by ADVA’s partners, the ICT solutions providers GCC Computers Ltd and ADAPTIT S.A., which will also provide ongoing technical support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005088/en/
“Cyta now has a synchronization network able to address the accuracy, efficiency and stability demands of 5G. With support for NTP, PTP and SyncE, our technology ensures that the new infrastructure meets the needs of Cyta’s legacy applications, ensuring a smooth migration to the precise packet timing that is critical for 5G services,” said Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Together with GCC’s and ADAPTIT S.A.’s teams, we’ve engineered a solution that fits Cyta’s exact requirements. It provides the sub-microsecond accuracy necessary for advanced mobile applications together with hardware redundancy for unbeatable resilience. What’s more, our Ensemble Controller network management technology makes it simple to operate.”
Prior to the deployment, Cyta’s timing network was based purely on frequency synchronization. It now distributes stable and accurate phase and time-of-day information, supporting the enhanced spectrum utilization needed for 5G. The solution features the OSA 5420 Series of grandmaster clocks, optimized for mobile backhaul and fronthaul in the radio access network. In the core, the OSA 5440 provides highest accuracy and availability with its dual multi-band, multi-constellation GNSS receiver and full hardware redundancy. The technology is remotely controlled by ADVA’s Ensemble Sync Director. This provides a powerful management platform, giving Cyta full visibility of its synchronization infrastructure and assuring perfect end-to-end timing.
“We’ve worked closely with Cyta to create a synchronization solution that fits its precise needs. Able to support both legacy and next-generation packet networking, Cyta’s new timing network is space- and power-efficient, assured by in-service PTP and GNSS monitoring and protected by hardware redundancy. Our engineers have also provided support at every stage of the process and made certain that the installation was carried out without any disruption to services,” commented Vasileios Karavasilis, commercial director, ADAPTIT S.A. “As a key distributor of ADVA’s Oscilloquartz solutions, we know all about the value of precise and reliable timing in mission-critical networks. Cyta is now prepared for mass 5G rollout with a synchronization architecture able to meet key challenges both now and in the future.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
About GCC Computers Ltd.
GCC Computers has a distinguished market presence in Cyprus as an ICT System Integrator and has built a strong reputation as the employer of the best technology professionals. For more than 30 years, GCC has been acknowledged with considerable success serving Public/Government, Telecommunications & Utilities, Banking/Finance and SME (Small-Medium-Enterprise) sectors with innovative solutions. GCC’s expertise and extensive partnerships help clients harness the technology power to thrive on change and guide their digital transformation journeys. For more information, please visit us at www.gcc.com.cy .
About ADAPTIT S.A.
ADAPTIT S.A. is a highly specialized System Integrator that combines latest technology trends to offer its clients innovative tailor-made solutions, according to their needs, and finally delivers high-quality TURNKEY PROJECTS, ensuring the highest possible performance of their investment. With a wide-range portfolio of networking solutions ADAPTIT provides networking expertise to Service Providers, Government Agencies and Enterprises. ADAPTIT S.A. has presence in most European countries, having delivered similar major projects to several Service Providers in Spain, Sweden, Finland, Portugal, Poland, Romania, Malta, Bulgaria, and Albania. For more information, please visit us at www.adaptit.gr .
About Cyta
Cyta is the leading provider of integrated electronic communications in Cyprus. Making the most of its technologically advanced networks, it offers a wide range of services and solutions to meet the ever-increasing demands of its residential and business customers for voice, data and content applications. With a pivotal role in the digital transformation of Cyprus, Cyta is deploying an island-wide, fiber-optic network, while it progressively upgrades its mobile network technology. It advances and maintains subsea and satellite networks for international connections of strategic importance that have established Cyprus as a regional telecommunications and connectivity hub in the Eastern Mediterranean. www.cyta.com.cy
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005088/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom